Navigation Links
Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
Date:1/10/2008

HOPKINTON, Mass., Jan. 10 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) President and CEO, Kevin Hrusovsky, will present at the JPMorgan 26th Annual Healthcare Conference in San Francisco, California, today, Thursday, January 10, 2008 at 2:00 p.m. PST. Mr. Hrusovsky will discuss Caliper's outlook for 2008, and the company's preliminary expectations regarding top-level revenue performance for 2007.

Based on preliminary, unaudited financial data the company expects to report total revenue of approximately $39.5 million for the fourth quarter of 2007 and approximately $140 million for the full year, in each case at the top end of the company's previously announced projections. Within fourth quarter revenue of approximately $39.5 million, combined product and service revenue is expected to be approximately $37 million, an increase of 16% over fourth quarter 2006 combined product and service revenue.

A live webcast of Mr. Hrusovsky's presentation can be accessed at http://www.metameetings.com/webcasts/jpmorgan/healthcare08/. An archived presentation will be available for 90 days.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

The statements in this press release regarding Caliper's anticipated total revenue for the fourth quarter of 2007 and for 2007 and its expected combined product and service revenue for the fourth quarter of 2007 are "forward- looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those Caliper expects or projects, including the risks that unexpected information may be received, or adjustments may be made, in the course of finalizing and analyzing the financial results, which could cause the final results to differ from these preliminary results. Further review of the company's financial results for 2007 could lead to revisions in the company's current expectations regarding revenue for this period and the portion of such revenue consisting of combined product and service revenue. Further information on risks faced by Caliper is included in risks discussed under the caption "Risk Factors" in Caliper's annual report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission on March 14, 2007, and in our other SEC reports and filings. These SEC reports and filings are available on a web site maintained by the SEC at http://www.sec.gov. Caliper expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Caliper's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Caliper is a registered trademark of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
4. Caliper Life Sciences Presentation at UBS Global Life Sciences Conference to be Webcast
5. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
6. Caliper Life Sciences to Participate in Deutsche Banks Healthcare Technology Industry Day
7. Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction
8. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... that it has become a Wonderware Certified System Integrator Partner. Huffman Engineering ... Schneider Electric Software. , “The System Integrator Partner certification gives customers confidence that ...
(Date:12/7/2016)... the association for the California life ... st Century Cures legislation in Congress. The bill passed ... and in the Senate on December 7 by a 94-5 ... , president & CEO of Biocom: "Today, Congress ... patients around the world. The measure culminates three years of ...
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, ... developing breakthrough immune modulatory medicines, announced today the initiation ... lead therapeutic candidate, LYC-30937- E nteric C oated, ... skin disease that is estimated to affect as many ... , with approximately 1.5 - 3 million cases ...
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... is opening applications to an early access program for SmartBiome -- a ... deep-sequencing with the simultaneous specific enrichment and detection of hundreds of different ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):